189 filings
6-K
NBTX
Nanobiotix
3 Jun 24
Current report (foreign)
6:00am
6-K
NBTX
Nanobiotix
28 May 24
Current report (foreign)
4:15pm
6-K
NBTX
Nanobiotix
23 May 24
NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
4:15pm
6-K
NBTX
Nanobiotix
22 May 24
NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update
6:00am
6-K
NBTX
Nanobiotix
21 May 24
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
5:30pm
6-K
v1jg2
16 May 24
Voting Rights and Shares Capital of the Company
4:15pm
6-K
seb4gq1o7yhi2bqtp
15 May 24
Current report (foreign)
4:15pm
6-K
6dd7zbzq9142n3hpzv
14 May 24
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
4:15pm
6-K
l3smw3
24 Apr 24
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
4:49pm
6-K
o5yjhls vvnal
17 Apr 24
Current report (foreign)
4:15pm
6-K
gebpobild3
10 Apr 24
Voting Rights and Shares Capital of the Company
4:15pm
6-K
7a0ikwjh6u
2 Apr 24
Current report (foreign)
4:15pm
6-K
3ma56mcoqrij31 7ga
6 Mar 24
Nanobiotix to Present at Upcoming Investor Conferences in March
4:15pm
6-K
ko2zhb6g b902n1
13 Feb 24
Voting Rights and Shares Capital of the Company
4:15pm
6-K
xhr iedqqvgu
31 Jan 24
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
4:15pm
6-K
yhqdxun2rhno3u7yo
29 Jan 24
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
4:15pm
6-K
lj4gv4y7q
11 Jan 24
Voting Rights and Shares Capital of the Company
5:50pm
6-K
p9nofhty7seg55z
26 Dec 23
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
6:05am
6-K
unom9n0co
13 Dec 23
Voting Rights and Shares Capital of the Company
4:15pm